AstraZeneca is posting bearish reversal signals

The failure to confirm the upside breakout of former 2020 top area at 9200 is a significant sign of weakness

Charts (2)

AstraZeneca, which produces pharmaceutical and medical products, posted 1H results: "Total Revenue increased by 12% (14% at CER) to 12,629 million dollars in the half, with growth across all three therapy areas and in every region. (...) Reported EPS of 1.17 dollars in the half, representing an increase of 108% (106% at CER). Core EPS increased by 24% (26% at CER) to 2.01 dollars. (...) An unchanged first interim dividend of 0.90 dollar per share." The company confirmed 2020 guidance.

From a chartist point of view, the failure to confirm the upside breakout of former 2020 top area at 9200 is a significant sign of weakness. In addition, the stock is posting a Dark Cloud Cover: a bearish reversal candlestick pattern while at the same time the weekly RSI is posting a bearish divergence: both are strong signals likely to favour a downturn. As a consequence, traders might consider short position below 50% retracement of the decline since the top (invalidation level of the candlestick pattern) at 9300 to target a decline towards June bottom area at 8100 and even January top at 7800. Alternatively, an upside breakout of 9300 would lower the immediate corrective risk and favour another test of the 10k area.

Source: GAIN Capital, TradingView

More from Equities

Disclaimer: The information on this web site is not targeted at the general public of any particular country. It is not intended for distribution to residents in any country where such distribution or use would contravene any local law or regulatory requirement. The information and opinions in this report are for general information use only and are not intended as an offer or solicitation with respect to the purchase or sale of any currency or CFD contract. All opinions and information contained in this report are subject to change without notice. This report has been prepared without regard to the specific investment objectives, financial situation and needs of any particular recipient. Any references to historical price movements or levels is informational based on our analysis and we do not represent or warranty that any such movements or levels are likely to reoccur in the future. While the information contained herein was obtained from sources believed to be reliable, author does not guarantee its accuracy or completeness, nor does author assume any liability for any direct, indirect or consequential loss that may result from the reliance by any person upon any such information or opinions.

Futures, Options on Futures, Foreign Exchange and other leveraged products involves significant risk of loss and is not suitable for all investors. Losses can exceed your deposits. Increasing leverage increases risk. Spot Gold and Silver contracts are not subject to regulation under the U.S. Commodity Exchange Act. Contracts for Difference (CFDs) are not available for US residents. Before deciding to trade forex and commodity futures, you should carefully consider your financial objectives, level of experience and risk appetite. Any opinions, news, research, analyses, prices or other information contained herein is intended as general information about the subject matter covered and is provided with the understanding that we do not provide any investment, legal, or tax advice. You should consult with appropriate counsel or other advisors on all investment, legal, or tax matters. References to or GAIN Capital refer to GAIN Capital Holdings Inc. and its subsidiaries. Please read Characteristics and Risks of Standardized Options.

Open an Account